The DOI matches its Crossref record; 222 of the 222 references it cites were found in a registry or an index.
Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline
Open accessAbstract
Background: Primary aldosteronism (PA), a primary adrenal disorder leading to excessive aldosterone production by one or both adrenal glands, is a common cause of hypertension. It is associated with an increased risk of cardiovascular complications compared with primary hypertension. Despite effective methods for diagnosing and treating PA, it remains markedly underdiagnosed and undertreated. Objective: To develop an updated guideline that provides a practical, clinical approach to identifying and managing PA to improve diagnosis rates and encourage targeted treatment. Methods: The Guideline Development Panel (GDP), composed of a multidisciplinary panel of clinical experts and experts in systemic review methodology, used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach to define 10 questions related to the diagnosis and treatment of PA. Systematic reviews were conducted for each question. The GDP used the GRADE Evidence to Decision (EtD) framework to consider contextual factors, such as stakeholder values and preferences, costs and required resources, cost-effectiveness, acceptability, feasibility, and the potential impact on health equity. Results: We suggest that all individuals with hypertension be screened for PA by measuring aldosterone and renin and determining the aldosterone to renin ratio, and that subsequent clinical care be guided by the results. We suggest that individuals with PA receive PA-specific therapy, either medical or surgical. In individuals who screen positive for PA, we suggest (1) commencement of PA-specific medical therapy in individuals who do not desire or are not candidates for surgery and in situations where the probability of lateralizing PA (excess aldosterone produced by one adrenal) is low based on screening results; and (2) aldosterone suppression testing in situations when screening results indicate an intermediate probability for lateralizing PA and individualized decision making confirms a desire to pursue eligibility for surgical therapy. In those who test positive by aldosterone suppression testing, and in those in whom screening results show a high probability of lateralizing PA (obviating the need for aldosterone suppression testing), we suggest adrenal lateralization with computed tomography scanning and adrenal venous sampling prior to deciding the treatment approach (medical vs surgical). In all individuals with PA and an adrenal adenoma, we suggest performing a 1-mg overnight dexamethasone suppression test. We suggest the use of mineralocorticoid receptor antagonists (MRAs) over epithelial sodium-channel (ENaC) inhibitors in the medical treatment of PA. We suggest the use of spironolactone over other MRAs, given its lower cost and greater availability; however, all MRAs, when titrated to equivalent potencies, are anticipated to have similar efficacy in treating PA. Thus, MRAs with greater mineralocorticoid receptor specificity and fewer androgen/progesterone receptor-mediated side effects may be preferred in some situations. In individuals receiving MRA therapy, we suggest monitoring renin and, in those whose hypertension remains uncontrolled and renin is suppressed, titrating the MRA to increase renin. Conclusion: These recommendations provide a practical framework for the diagnosis and treatment of PA. They are based on currently available literature and take into consideration outcomes that are important to key stakeholders. The goal is to increase identification of individuals with PA and, by initiating PA-specific medical or surgical therapy, improve blood pressure control and reduce PA-associated adverse cardiovascular events. The guidelines also highlight important knowledge gaps in PA diagnosis and management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–222 of 222
Pintus, G., Seccia, T. M., Amar, L., Azizi, M., Riester, A., Reincke, M., Widimsky, J., Jr., Naruse, M., Kocjan, T., Negro, A., et al. (2024) · Hypertension · doi:10.1161/hypertensionaha.124.22721 · Cited by 17
Self-citationDiagnostic Accuracy of the Aldosterone–to–Active Renin Ratio for Detecting Primary Aldosteronism
Pilz, S., Keppel, M. H., Trummer, C., Theiler‐Schwetz, V., Pandis, M., Borzan, V., Pittrof, M., Obermayer-Pietsch, B. M., Grübler, M. R., Verheyen, N., et al. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00145 · Cited by 16
Okubo, J., Frudit, P., Cavalcante, A. C. B. S., Maciel, A. A. W., Freitas, T. C., Pilan, B., Fagundes, G. F. C., Queiroz, N. L., Stumpf, M. A. M., Souza, V. C. M., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae142 · Cited by 16
Ho, W.-Y., Hsiao, C.-C., Wu, P., Chen, J., Tu, Y., Wu, V., & Chen, J. (2024) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223241239775 · Cited by 16
The value of plasma metanephrine measurements during adrenal vein sampling
Carroll, R. W., Corley, B., Feltham, J., Whitfield, P., Park, W., Howard, R., Yssel, M., Phillips, I., Harper, S., & Yang, J. (2023) · Endocrine Connections · doi:10.1530/ec-23-0300 · Cited by 14
Self-citationChristou, F., Pivin, E., Denys, A. L., Abid, K., Zingg, T., Matter, M., Péchère-Bertschi, A., Maillard, M. P., Grouzmann, E., & Wuerzner, G. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.842968 · Cited by 13
Enhancing the Trustworthiness of the Endocrine Society’s Clinical Practice Guidelines
McCartney, C. R., Corrigan, M. D., Drake, M. T., Fuleihan, G. E., Korytkowski, M. T., Lash, R. W., Lieb, D. C., McCall, A. L., Muniyappa, R., Piggott, T., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac290 · Cited by 13
Self-citationGenovesi, S., Antolini, L., Orlando, A., Tassistro, E., Giussani, M., Nava, E., Turolo, L., Manolopoulou, J., Parati, G., & Morganti, A. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001571 · Cited by 12
Arnold, N., Hermanns, I., Schulz, A., Hahad, O., Schmitt, V. H., Panova‐Noeva, M., Prochaska, J. H., Binder, H., Pfeiffer, N., Beutel, M. E., et al. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac019 · Cited by 12
Nakano, Y., Murakami, M., Hara, K., Fukuda, T., Horino, M., Takeuchi, A., Niitsu, Y., Shiba, K., Tsujimoto, K., Komiya, C., et al. (2022) · Clinical Endocrinology · doi:10.1111/cen.14849 · Cited by 12
Mineralocorticoid antagonists and ENaC inhibitors in hyperaldosteronism
Hill, M. A., & Sowers, J. R. (2019) · Journal of Clinical Hypertension · doi:10.1111/jch.13566 · Cited by 10
Liu, Z., Deng, X., Luo, L., Li, S., Li, M., Deng, Q., Zhong, W., & Luo, Q. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001906 · Cited by 10
Kubo, H., Tsurutani, Y., Inoue, K., Watanabe, K., Yamazaki, Y., Sunouchi, T., Hoshino, Y., Hirose, R., Katsuragawa, S., Tannai, H., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267732 · Cited by 10
Adrenalectomy approach and outcomes according to surgeon volume
Ginzberg, S. P., Gasior, J. A., Kelz, L. R., Passman, J. E., Ballester, J. M. S., Roses, R. E., Fraker, D. L., & Wachtel, H. (2023) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2023.10.042 · Cited by 10
68Ga-pentixafor PET/CT in guiding surgical management of primary aldosteronism
Zheng, G., Ding, J., Gao, Y., Liu, S., Yan, X., Wang, W., Zhao, Y., Wang, Z., Huo, L., Tong, A., et al. (2025) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2025.100384 · Cited by 10
Liu, W., Zhang, J., Yang, Y., Jin, Y., Li, Z., You, L., Luo, J., & Su, X. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1756-4937 · Cited by 9
Izzo, J. L., Hong, M., Hussain, T., & Osmond, P. (2019) · Journal of Clinical Hypertension · doi:10.1111/jch.13567 · Cited by 7
Zhou, Y., Zhang, H., Luo, J., Hou, J., Xue, Q., Wang, X., Guo, H., Wang, P., & Wang, P. (2023) · American Journal of Hypertension · doi:10.1093/ajh/hpad089 · Cited by 6
Adherence and blood pressure control in patients with primary aldosteronism
Nguyen, T. M. P. N., Štrauch, B., Petrák, O., Krátká, Z., Holaj, R., Kurcová, I., Marešová, V., Pilková, A., Hartinger, J. M., Waldauf, P., et al. (2022) · Blood Pressure · doi:10.1080/08037051.2022.2061416 · Cited by 5
Arjani, S., Bostonian, T. J., Prasath, V., Quinn, P. L., & Chokshi, R. J. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01821-7 · Cited by 5
Chen, F., Dai, J., Zhao, J., Huang, X., He, W., Xu, J., & Sun, F. (2023) · Journal of Clinical Hypertension · doi:10.1111/jch.14725 · Cited by 5
Mohan, S., Shariq, O. A., Andrews, J. C., & Young, W. F. (2024) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2024.12.587 · Cited by 2
Self-citation
Metadata
- Authors
- Adler, G. K., Stowasser, M., Correa, R. R., Khan, N., Kline, G., McGowan, M. J., Mulatero, P., Murad, M. H., Touyz, R. M., Vaidya, A., Williams, T. A., Yang, J., Young, W. F., Zennaro, M.-C., & Brito, J. P.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2025-07-14
- Volume
- 110
- Issue
- 9
- Pages
- 2453-2495
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W4412473622
- Cited by
- 355
- References
- 222
- FWCI
- 211.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.